Predicate |
Object |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-606 |
filingDate |
2005-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2008-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2008501707-A |
titleOfInvention |
Methods for treating mast cell disorders |
abstract |
The present invention provides a method of inhibiting mast cell activity by administering a selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The invention also provides a method for treating or preventing a condition associated with unwanted mast cell activity in an individual comprising administering an effective amount of a selective PI3Kδ inhibitor. The methods of the invention are particularly useful for treating or preventing conditions (or symptoms associated with conditions) mediated by immunoglobulin receptor cross-linking on the surface of mast cells. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012521994-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012524126-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9771316-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2014112646-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105263899-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019522678-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012533541-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015155436-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105263899-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014112646-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10577369-B2 |
priorityDate |
2004-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |